{"entity":{"id":"christos-karapetis","kind":"person","name":"Christos Karapetis","aka":[],"tldr":"Australian medical oncologist whose landmark NEJM analysis showed KRAS mutation predicts lack of benefit from cetuximab in colorectal cancer.","summary":"Christos (Chris) Karapetis is a Professor of medical oncology at Flinders University and Flinders Medical Centre in Adelaide and serves on the Board of Directors of the Australasian Gastro-Intestinal Trials Group. He was first author of the 2008 New England Journal of Medicine analysis of the CO.17 trial establishing KRAS mutation status as a predictive biomarker for cetuximab in advanced colorectal cancer, and has led numerous AGITG trials.","asOf":"2026-09-10","links":[{"label":"Society page","url":"https://gicancer.org.au/about-us/board-of-directors/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Karapetis+CS%5BAuthor%5D"}],"tags":["clinician-scientist","colorectal cancer","clinical trials"],"related":[],"cancers":["colorectal"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["agitg"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Board Director","institutionId":"agitg","specialisms":["Medical oncology","Colorectal cancer","Biomarkers","Clinical trials"],"profiles":[{"label":"Society page","url":"https://gicancer.org.au/about-us/board-of-directors/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Karapetis+CS%5BAuthor%5D"}],"papers":[{"title":"K-ras mutations and benefit from cetuximab in advanced colorectal cancer","journal":"New England Journal of Medicine","year":2008,"url":"https://doi.org/10.1056/NEJMoa0804385","doi":"10.1056/NEJMoa0804385"}]},"route":"/people/christos-karapetis/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"}],"company":[{"id":"agitg","kind":"company","name":"Australasian Gastro-Intestinal Trials Group","route":"/companies/agitg/"}],"paper":[{"id":"paper-karapetis-kras-cetuximab-colorectal-nejm-2008","kind":"paper","name":"K-ras mutations and benefit from cetuximab in advanced colorectal cancer","route":"/key-papers/paper-karapetis-kras-cetuximab-colorectal-nejm-2008/"}]}}